Risperidone Long-Acting Injection Suppliers & Bulk Manufacturers
Available Forms: Long-Acting Injection
Available Strengths: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes
Reference Brands: Risperdal Consta(US &EU)
Category:
Antipsychotropic Drugs
Risperidone LAI is a long-acting antipsychotic injection used biweekly to treat schizophrenia and bipolar disorder. Marketed as Risperdal Consta, it ensures consistent medication delivery and enhances adherence. Approved in the US and EU, it plays a vital role in long-term psychiatric management with ongoing interest in generic alternatives.
Risperidone Long-Acting Injection is available in Long-Acting Injection
and strengths such as 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Risperidone Long-Acting Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Risperidone Long-Acting Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Risperidone Long-Acting Injection, commonly marketed as Risperdal Consta, is a second-generation antipsychotic approved in both the US (FDA) and EU (EMA) for the treatment of schizophrenia and maintenance therapy in bipolar disorder. It is administered intramuscularly every two weeks and provides steady plasma levels, improving adherence in patients with chronic psychosis. The drug requires prior oral risperidone trial before initiating long-acting therapy. In the EU, it is approved under centralized and national procedures. In the US, it holds FDA approval under NDA. Its prolonged-release formulation is protected by a series of patents, though generic development has begun in select markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing